Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Proteomics Products May Reach $1.7 Billion by 2006

By Biotechdaily staff writers
Posted on 20 May 2002
By 2006, total revenues of proteomics-related products are forecast to approach US$1.7 billion, according to a new report from Business Communications Co. More...
(Proteomics: An Assessment of Technology and Commercial Potential, BCI, Inc., Norwalk, CT, USA). Since revenues for selected proteomics products totaled $720 million in 2001, the 2006 forecast would represent an average annual growth rate (AAGR) of just over 18%. This growth is largely due to a boom in scientific discoveries stemming from the human genome project and from advances in high-throughput technologies for protein studies. Other contributing factors are increases in funding for research and an increased interest in drug discovery from pharmaceutical and biotechnology companies.

Today, researchers can analyze protein expression in an entire cell rather than studying individual proteins, notes the report. Newer techniques allow scientists to isolate proteins and identify them more quickly. The development of new technologies for studying proteins has led to a rapid growth in industries supplying instruments and reagents for proteomics studies. In turn, this had made a variety of products easily available from companies eager to compete in the new market.

The market for mass spectroscopy for proteomics represents more than 40% of the total market and is forecast to double in five years, from $300 million in 2001 to $603 million by 2006. The nascent market for protein chips and bioinformatics is expected to rise from $114 million in 2001 to $275 million in 2006. Two-dimensional electrophoresis will see lower growth (11%), while capillary electrophoresis will rise at an AAGR of over 15% during the period.

Factors influencing the growth of the market for drug delivery instruments and services include the continuing investments of national governments into technology-based companies and technology-based not-for-profit research, the push by big pharmaceutical companies to fill their blockbuster pipelines, and efforts by small biotechnology companies to become bigger companies. As all of these groups continue their efforts, says BCC, they will in turn drive the development of new instruments and new technologies.





Related Links:
BCC

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
New
Gold Member
Platelet Function Analyzer
PL-12
CMV CLIA Diagnostic
CLIA CMV IgA Screen Group
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Alzheimer’s pathology can start 15 to 20 years before symptoms, and validated tools that reach patients earlier help pave the way for earlier detection. (Image Credit: Adobe Stock)

Alzheimer’s Blood Test Becomes First FDA-Cleared Option for Adults as Young as 40

C2N Diagnostics’ PrecivityAD2 blood test was cleared by the U.S. Food and Drug Administration (FDA) on August 20, 2026, for adults as young as 40 who are experiencing signs of cognitive impairment, according... Read more

Pathology

view channel
Image: Adrenal gland tumor stained with hematoxylin and eosin (top) and CYP11B2 (bottom) (Photo courtesy of Christofer Juhlin)

Simple Immunohistochemical Size Ratio Improves Classification of Primary Aldosteronism

Primary aldosteronism is a common but underdiagnosed cause of hypertension, in which excess aldosterone promotes salt retention and raises blood pressure. Identifying the dominant source of hormone overproduction... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.